Insights, Alerts

& Trends

Life Science Industry News

Insights, Alerts & Trends | Life Science IAT Life Science IAT  OCTOBER 27

Life Science Industry News

The robotic surgery tool market, in vivo gene editing and more

Top of the News:

An FDA advisory panel has voted to give the Pfizer COVID-19 vaccine for children emergency authorization.


A group of bipartisan Senators have introduced a bill that is supposed to help seniors access care in less time, Policy & Medicine writes.

After being found to have taken donations from large pharmaceutical companies, Senator Bob Menendez, D-N.J., has said he will not support the House plan to allow Medicare to negotiate drug costs, Salon reports.


In a phone call with reporters on the results from the Substance Abuse and Mental Health Services Administration’s annual National Survey on Drug Use and Health, Captain Michael King, PhD, MSW, acting director of the SAMHSA’s Center for Behavioral Health Statistics and Quality announced that roughly 40 million Americans struggled with a substance use disorder in 2020, Medpage Today writes.


A study published in Cardiovascular Research has identified how environmental factors such as pollution affect cardiovascular diseases, Medical News Today writes.

Professional Development:

Here’s the case for a shorter work week.


Contract-based packaging organization Tjoapack has acquired healthcare packaging company Pharma Packaging Solutions, Contract Pharma writes.

Robotic surgery tools have begun to dominate the market, after some delays thanks to COVID-19, Medtech Dive reports.


Roche Holding AG’s refillable eye implant may serve to dethrone Eylea’s own implant, Biopharma Dive writes.

Intellia Therapeutics and LogicBio Therapeutics have re-inspired interest in in vivo gene editing thanks to research they provided in their most recent data provisions they offered at a European Society of Gene and Cell Therapy conference, Fierce Biotech reports.


A ruling back in April of this year from the US Court of Appeals by the District of Columbia against the FDA regarding the organization’s methods of classifying drugs and medical devices has taken its toll on the stocks of the company the trial was over, Endpoints writes.

Errant Gene Therapeutics is suing Bluebird Bio for allegedly infringing on its patent for a recombinant vector used to make a treatment for rare blood disorders, Fierce Pharma reports.